Citations

Showing 10 of 108081 citations.

CNS T-Cell Lymphoma Many Years After Hemophagocytic Lymphohistiocytosis
Zhu, Agnes , Itoh, Christopher Y. , Coburn, Ryan P., Lu, Lauren , Mustafa, Rafid , Lu, Lauren Xiaoyuan , Coburn, Ryan P

Mayo Clinic

Neurology | March 28, 2023 | Volume: 101 | Issue: 8 | Pages: 369-370

10.1212/wnl.0000000000207244 | PMID 36977599 Get It

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)
Boughey, Judy C. , Rosenkranz, Kari M. , McCall, Linda, Haffty, Bruce G. , Cuttino, Laurie W., Kubicky, Charlotte Dai, Le‐Petross, Huong T. , Giuliano, Armando E. , Hahn, Olwen, Boughey, JC , Haffty, Bruce G , Hunt, KK , Carey, Lisa A , Partridge, Ann H , Ballman, Karla V. , Zee, Kimberly J. Van , Hunt, Kelly K. , Carey, Lisa A. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 28, 2023 | Volume: 41 | Issue: 17 | Pages: 3184-3193

10.1200/jco.22.02553 | PMID 36977292 Get It

PURPOSE Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible. Patients underwent lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds. The primary end point was cumulative incidence of local recurrence (LR) at 5 years with an a priori rate of clinical acceptability of <8%. RESULTS Among 270 women enrolled between November 2012 and August 2016, there were 204 eligible patients who underwent protocol-directed BCT. The median age was 61 years (range, 40-87 years). At a median follow-up of 66.4 months (range, 1.3-90.6 months), six patients developed LR for an estimated 5-year cumulative incidence of LR of 3.1% (95% CI, 1.3 to 6.4). Patient age, number of sites of preoperative biopsy–proven BC, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories were not associated with LR risk. Exploratory analysis showed that the 5-year LR rate in patients without preoperative magnetic resonance imaging (MRI; n = 15) was 22.6% compared with 1.7% in patients with a preoperative MRI (n = 189; P = .002). CONCLUSION The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year LR rate for MIBC. This evidence supports BCT as a reasonable surgical option for women with two to three ipsilateral foci, particularly among patients with disease evaluated with preoperative breast MRI.
Proposed dietary recommendations for iron overload: a guide for physician practice
Saleh, Hasan , Seaman, Leigh Ann Kenda, Palmer, William C.

Mayo Clinic

Current Opinion in Gastroenterology | March 28, 2023 | Volume: 39 | Issue: 3 | Pages: 146-149

10.1097/mog.0000000000000923 | PMID 36976854 Get It

Purpose of review Iron overload disorders such as hemochromatosis involve unregulated absorption of dietary iron, leading to excessive iron accumulation in multiple organs. Phlebotomy is the standard of care for removal of excess iron, but dietary modification is not standardized in practice. The purpose of this article is to help standardize hemochromatosis diet counseling based on commonly asked patient questions. Recent findings The clinical benefit regarding dietary modification in iron overload patients is limited due to lack of large clinical trials, but preliminary results are promising. Recent studies suggest diet modification could reduce iron burden in hemochromatosis patients resulting in less annual phlebotomy as supported through small patient studies, concepts of physiology, and animal studies. Summary This article is a guide for physicians to counsel hemochromatosis patients based on commonly asked questions such as foods to avoid, foods to consume, use of alcohol, and use of supplements. The goal of this guide is to help standardize hemochromatosis diet counseling to reduce phlebotomy amount in patients. Standardization of diet counseling could help facilitate future patient studies to analyze the clinical significance.
Leuprolide Protects Ovarian Reserve in Adolescents Undergoing Gonadotoxic Therapy
Hoyos-Martínez, Alfonso , Okcu, M. Fatih , Horne, Vincent E. , Allen-Rhoades, Wendy, Scheurer, Michael E. , Allen‐Rhoades, Wendy

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | March 28, 2023 | Volume: 12 | Issue: 6 | Pages: 828-834

10.1089/jayao.2022.0128 | PMID 36976803 Get It

Purpose: Treatment sequelae compromising reproductive health are highly prevalent in childhood cancer survivors, and a main determinant of health and quality of life. Follicular reserve determines ovarian function life span; thus, its preservation is important in the care of female survivors. Anti-Müllerian hormone (AMH) is a biomarker to measure functional ovarian reserve. We aimed to evaluate the effect of leuprolide during gonadotoxic therapy on pubertal females' post-treatment functional ovarian reserve using AMH levels. Methods: We conducted a single-center retrospective study including all pubertal females who had undergone gonadotoxic treatments between January 2010 and April 2020, and had an AMH level after completion of therapy. We used multivariable linear regressions to compare AMH-level beta coefficients in patients stratified by gonadotoxic risk, adjusting for leuprolide use. Results: Fifty-two females meeting study eligibility were included, of which 35 received leuprolide. The use of leuprolide was associated with higher post-treatment AMH levels in the lower gonadotoxic risk group (beta 2.74, 95% CI 0.97–4.51; p = 0.004). This association was lost in the higher gonadotoxic risk groups. Conclusions: Leuprolide may have a protective effect on the functional ovarian reserve. However, this is limited by increasing treatment gonadotoxicity. Larger, prospective studies are needed to elucidate the potential benefits of gonadotropin-releasing hormone agonist on preservation of ovarian reserve among children receiving gonadotoxic therapies, as cancer survivors.
Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam
Vasquez, Alejandra , Youssef, Paul E., Wirrell, Elaine

Mayo Clinic

Expert Review of Neurotherapeutics | March 28, 2023 | Volume: 23 | Issue: 4 | Pages: 297-309

10.1080/14737175.2023.2195550 | PMID 36975187 Get It

Lymphangioleiomyomatosis in lymph node cytology: Another “Floating Island” to visit
Jawaid, Tabinda , Swanson, Amy A. , Bois, Melanie C. , Folpe, Andrew L. , Rivera, Michael , Hartley, Christopher , Sturgis, Charles D. , Hartley, Christopher P., Sturgis, Charles D , Hartley, Christopher P

Mayo Clinic

Diagnostic Cytopathology | March 28, 2023 | Volume: 51 | Issue: 6 | Pages: No page available

10.1002/dc.25131 | PMID 36975549 Get It

AbstractLymphangioleiomyomatosis (LAM) is a rare disease with variable presentations. The neoplastic cells in LAM demonstrate a unique and diagnostically important “myomelanocytic” phenotype. Cytologic reports of LAM are infrequent and have not in the past emphasized the floating island pattern in which circumscribed aggregates of lesional cells are rimmed by appliques of flattened endothelium. This case illustrates the cytology of LAM and emphasizes that the floating island cytoarchitectural pattern more classically associated with entities such as hepatocellular carcinomas may be seen in cytological preparations of LAM at unanticipated body sites.
Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
Ahuja, Dhruv, Jairath, Vipul , Singh, Siddharth , Jairath, Vipul , Jairath, Vipul , Murad, Mohammad Hassan, Jairath, V , Jairath, V , Jairath, Vipul , Ahuja, Dhruv , Murad, M. Hassan , Ma, Christopher

Mayo Clinic

American Journal of Gastroenterology | March 28, 2023 | Volume: 118 | Issue: 9 | Pages: 1618-1625

10.14309/ajg.0000000000002263 | PMID 36976548 Get It

INTRODUCTION: Rapidity of symptom resolution informs treatment choice in patients with moderate-severe ulcerative colitis (UC). We conducted a systematic review and network meta-analysis comparing early symptomatic remission with approved therapies. METHODS: Through a systematic literature review to December 31, 2022, we identified randomized trials in adult outpatients with moderate-severe UC treated with approved therapies (tumor necrosis factor α antagonists, vedolizumab, ustekinumab, janus kinase inhibitors, or ozanimod), compared with each other or placebo, reporting rates of symptomatic remission (based on partial Mayo score, with resolution of rectal bleeding and near-normalization of stool frequency) at weeks 2, 4, and/or 6. We performed random-effects network meta-analysis using a frequentist approach and estimated relative risk (RR) and 95% confidence interval values. RESULTS: On network meta-analysis, upadacitinib was more effective than all agents in achieving symptomatic remission at weeks 2 (range of RR, 2.85–6.27), 4 (range of RR, 1.78–2.37), and 6 (range of RR, 1.84–2.79). Tumor necrosis factor α antagonists and filgotinib, but not ustekinumab and vedolizumab, were more effective than ozanimod in achieving symptomatic remission at week 2, but not at weeks 4 and 6. With approximately 10% placebo-treated patients achieving symptomatic remission at 2 weeks, we estimated 68%, 22%, 23.7%, 23.9%, 22.2%, 18.4%, 15.7%, and 10.9% of upadacitinib-, filgotinib-, infliximab-, adalimumab-, golimumab-, ustekinumab-, vedolizumab-, and ozanimod-treated patients would achieve early symptomatic remission, ustekinumab and vedolizumab achieving rapid remission only in biologic-naïve patients. DISCUSSION: In a systematic review and network meta-analysis, upadacitinib was most effective in achieving early symptomatic remission, whereas ozanimod was relatively slower acting.
APOE and immunity: Research highlights
Kloske, Courtney M. , Barnum, Christopher J. , Batista, André F., Bradshaw, Elizabeth M. , Bu, Guojun , Dennison, Jessica , Gearon, Mary D, Goate, Alison , Haass, Christian , Hu, William T. , Huggins, Lenique , Jones, Nahdia S. , Liddelow, Shane A. , Marsh, Samuel E. , Petersen, Melissa, Piña‐Escudero, Stefanie Danielle , Reiman, Eric M. , Sexton, Claire E. , TCW, Julia , Wallings, Rebecca L. , Weninger, Stacie, Wharton, Whitney , Wishard, Tyler J. , Worley, Susan, Carrillo, María C. , Sexton, Claire , Bu, Guojun , Goate, Alison M , Hu, William T. , Brickman, Adam M. , Heneka, Michael T. , Koldamova, Radosveta P. , Lemere, Cynthia Ann , Marcora, Edoardo , Nielsen, Henrietta M. , Petersen, Kellen K. , Petersen, Melissa , Qiu, Wei Qiao , Quiroz, Yakeel T. , Tansey, Malú G. , Teunissen, Charlotte E. , Tijms, Betty M. , Kant, Rik van der , Wilcock, Donna M. , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | March 28, 2023 | Volume: 19 | Issue: 6 | Pages: 2677-2696

10.1002/alz.13020 | PMID 36975090 Get It

AbstractINTRODUCTIONAt the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias.METHODSThe meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry.RESULTSDuring the 4‐day meeting, presenters illuminated aspects of the cross‐talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]).DISCUSSIONThis manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Increased Resolution of Time-of-Flight MR Angiography at Higher Field Strength
Lakhani, Dhairya A. , Zhou, Xiangzhi , Tao, Shengzhen , Middlebrooks, Erik H. , Middlebrooks, Erik H , Lakhani, Dhairya

Mayo Clinic

Radiology | March 28, 2023 | Volume: 307 | Issue: 4 | Pages: No page available

10.1148/radiol.222619 | PMID 36975817 Get It

Racial and Ethnic Disparities in the Use and Outcomes of Transcatheter Mitral Valve Replacement: Analysis From the National Inpatient Sample Database
Ismayl, Mahmoud , Abbasi, Muhannad , Al‐Abcha, Abdullah , El‐Am, Edward , Walters, Ryan W. , Goldsweig, Andrew M. , Alkhouli, Mohamad , Guerrero, Mayra , Anavekar, Nandan S., Abbasi, Muhannad Aboud , Alkhouli, Mohamad , Guerrero, Mayra E , Goldsweig, Andrew M , Al-Abcha, Abdulah , Ismayl, Mahmoud

Mayo Clinic

Journal of the American Heart Association | March 28, 2023 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/jaha.122.028999 | PMID 36974752 Get It

Background Racial and ethnic disparities in outcomes exist following many cardiac procedures. Transcatheter mitral valve replacement (TMVR) has grown as an alternative to mitral valve surgery for patients at high surgical risk. The outcomes of TMVR by race and ethnicity are unknown. We aimed to evaluate racial and ethnic disparities in the outcomes of TMVR. Methods and Results We analyzed the National Inpatient Sample database from 2016 to 2020 to identify hospitalizations for TMVR. Racial and ethnic disparities in TMVR outcomes were determined using logistic regression models. Between 2016 and 2020, 5005 hospitalizations for TMVR were identified, composed of 3840 (76.7%) White race, 505 (10.1%) Black race, 315 (6.3%) Hispanic ethnicity, and 345 (6.9%) from other races (Asian, Pacific Islander, American Indian or Alaska Native, Other). Compared with other racial and ethnic groups, Black patients were significantly younger and more likely to be women (both P <0.01). There were no significant differences between White, Black, and Hispanic patients in in‐hospital mortality (5.2% versus 5.0% versus <3.5%; P =0.89) and procedural complications, including heart block ( P =0.91), permanent pacemaker ( P =0.49), prosthetic valve dysfunction ( P =0.45), stroke ( P =0.37), acute kidney injury ( P =0.32), major bleeding ( P =0.23), and blood transfusion ( P =0.92), even after adjustment for baseline characteristics. Adjusted vascular complications were higher in Black compared with White patients ( P =0.03). Trend analysis revealed a significant increase in TMVR in all racial and ethnic groups from 2016 to 2020 ( P trend <0.05). Conclusions Between 2016 and 2020, Black and Hispanic patients undergoing TMVR had similar in‐hospital outcomes compared with White patients, except for higher vascular complications in Black patients. Further comparative studies of TMVR in clinically similar White patients and other racial and ethnic groups are warranted to confirm our findings.